Evidence of CV risk with rosiglitazone conflicting

摘要

Debate over the cardiovascular safety of rosiglitazone continues this week as conflicting data emerge.A study, published online in JAMA (28 June 2010), shows that, among more than 227,000 patients aged 65 years and over, rosiglitazone was associated with an increased risk of stroke, heart failure and all-cause mortality, and an increased risk of a composite of acute myocardial infarction (MI), stroke, heart failure or all-cause mortality, compared with pioglitazone.The study found no differences in the risk of MI between the two medicines.